CPhI Online

- Biopharma News

BMS expands global footprint with new cell therapy manufacturing facility

23 Feb 2021

The new site will be equipped to enable quick ramp-up of capacity for clinical and commercial cell therapy products

Construction is underway for a new cell therapy manufacturing facility in Devens, Massachusetts, a part of Bristol Myers Squibb’s (BMS's) investment to support clinical and commercial manufacturing of cell therapies for patients with aggressive hematological cancers.

The new 244,000-sq. ft cell therapy facility will be located on BMS’s current 89-acre Devens campus that supports process development, clinical manufacturing and commercial manufacturing for biologics medicines, including an immuno-oncology medicine.

It will add to the company’s already established state-of-the-art cell therapy manufacturing network with cutting-edge technologies and highly trained manufacturing teams.

The Devens site will be equipped to enable quick ramp-up of capacity for clinical and commercial cell therapy products.

The new cell therapy facility allows accelerated career development for current and prospective employees across biologics and cell therapies on a single campus, with employees having access to all existing campus amenities. The company plans to hire several hundred employees during the next few years to support the new operations.

The Devens campus is part of BMS’s growing presence in Massachusetts; it also operates two R&D facilities in Cambridge, MA, and will be bringing those two sites together into a new building at Cambridge Crossing in 2023.

According to Ann Lee, head, Cell Therapy Development & Operations, BMS, the new facility in the Boston area will include "many next-generation technologies and the latest integrated digital systems".

Related Content